• 1
    Struewing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith SA, et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995; 57: 1-7.
  • 2
    Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, et al. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995; 57: 1284-97.
  • 3
    Tonin P, Weber B, Offit K, Crouch F, Rebbeck TR, Neuhausen S, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996; 2: 1179-83.
  • 4
    Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995; 11: 198-200.
  • 5
    Roa B, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14: 188-90.
  • 6
    Berman DB, Wagnercostalas J, Schultz DC, Lynch HT, Daly M, Godwin AK. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families--A genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet 1996; 58: 1166-76.
  • 7
    Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
  • 8
    Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12: 333-7.
  • 9
    Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody L, Kaback M, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996; 14: 185-7.
  • 10
    Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, et al. Recurrent BRCA2 6174delT Mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996; 13: 126-8.
  • 11
    FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996; 334: 143-9.
  • 12
    Offit K, Gilewski T, McGuire P, Schluger A, Hampel H, Brown K, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996; 347: 1643-5.
  • 13
    Page DL, Anderson TJ, Sakamoto G. Infiltrating carcinoma: major histological types. In: PageDL, AndersonTJ, editors. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987: 193-235.
  • 14
    Black MM, Barclay TH, Hankey BF. Prognosis in breast cancer utilizing histologic characteristics of the primary tumor. Cancer 1975; 36: 2048-55.
  • 15
    Elston CW. Grading of invasive carcinoma of the breast. In: PageDL, AndersonTJ, editors. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987: 300-11.
  • 16
    Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC. The pathology of invasive breast cancer. A syllabus derived from the findings of the National Surgical Adjuvant Breast Project (No. 4). Cancer 1975; 36: 1-85.
  • 17
    Knight W, Livingston R, Gregory E, McGuire W. Estrogen receptor as an independent prognostic marker for early recurrence in breast cancer. Cancer Res 1977; 37: 4669-73.
  • 18
    Futreal PA, Lui Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994; 266: 120-2.
  • 19
    Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996; 13: 238-40.
  • 20
    Teng D H-F, Bogden R, Mitchell J, Baumgard M, Bell R, Berry S, et al. Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet 1996; 13: 241-4.
  • 21
    Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 1996; 13: 245-7.
  • 22
    Cancer in Canada 1990. Catalogue number 82-218, Statistics Canada. Ottawa, Ontario, Canada: Statistics Canada, 1994.
  • 23
    Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996; 77: 697-709.
  • 24
    Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996; 56: 471-4.
  • 25
    Sobol H, Stoppa-Lyonnet D, Bressac-de-Paillerets B, Peyrat J-P, Kerangueven F, Janin N, et al. Truncation at conserved terminal regions of BRCA1 protein in associated with highly proliferating hereditary breast cancers. Cancer Res 1996; 56: 3216-9.